Drug Approval | June 17, 2024
Imfinzi approved in the US for endometrial cancer
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's
Subscribe To Our Newsletter & Stay Updated
